The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).
 
Guillermo de Velasco
Honoraria - Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD; MSD; Novartis; Pfizer
Research Funding - Ipsen
Other Relationship - Janssen
 
Álvaro Ruiz-Granados
No Relationships to Disclose
 
Oscar Reig
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen
 
Francesco Massari
No Relationships to Disclose
 
Miguel Angel Climent Duran
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Janssen-Cilag; Merck; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche
 
Elena Verzoni
Consulting or Advisory Role - Janssen Oncology; Pfizer
Speakers' Bureau - Ipsen; Novartis
 
Jeffrey Graham
No Relationships to Disclose
 
Roberto Llarena
No Relationships to Disclose
 
Michele De Tursi
No Relationships to Disclose
 
Frede Donskov
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Clara Iglesias
No Relationships to Disclose
 
Hardev S. Pandha
No Relationships to Disclose
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer; PharmaMar
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD